Anemia Associated with Lead Poisoning
At a Glance
Lead poisoning can cause anemia. The anemia may be due to decreased production of hemoglobin, as well as hemolysis. Signs of hemolysis may include scleral icterus and jaundice. Other symptoms associated with lead poisoning are covered in the chapter on laboratory testing for lead.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
If a hemolytic anemia is in the differential, haptoglobin, lactate dehydrogenase (LDH), and bilirubin can be useful. Haptoglobin scavenges free hemoglobin and is low in hemolytic anemia.
Hemolysis may also lead to elevated LDH and bilirubin. LDH is present in red cells, and hemolysis causes release into the plasma. Bilirubin is a breakdown product of hemoglobin and becomes elevated as hemoglobin is released. Indirect hyperbilirubinemia is typically seen in hemolysis.
Review of the peripheral smear is crucial. Patients with lead poisoning will often show basophilic stippling. Microcytosis and hypochromia may be present, and reticulocyte counts may be elevated.
The direct antiglobulin test (DAT, direct Coombs test) should be negative (see chapter on laboratory testing for lead).
Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?
Haptoglobin is very sensitive but not specific for clinically significant hemolysis, as even small amounts of free hemoglobin can deplete normal levels of serum haptoglobin. It may also be decreased in liver disease. As haptoglobin is an acute phase reactant, it may be elevated in a number of diseases leading to difficulties in interpretation.
LDH is present in all tissues, including red cells, so elevations are consistent with hemolysis but very nonspecific, as any cellular damage may affect levels. As such, there are many other disorders that may cause an elevated LDH.
Other disorders may be associated with basophilic stippling.
Test Results Indicative of the Disorder
|Bilriubin, Indirect||LDH||Haptoglobin||Peripheral Smear||Lead|
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Testosterone Prescribing Trends in the United States Between 2002 and 2016
- The Future of Food and Drug Regulation: Trump Administration Proposes Reorganization of FDA, USDA
- Popliteal Sciatic Nerve Block May Increase Time to First Opioid Request in Diabetic Peripheral Neuropathy
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Subclinical Hypothyroidism: Controversies in Testing and Treatment